ARTICLE | Clinical News
NM-3 isocoumarin: Began Phase I trial
January 16, 2001 8:00 AM UTC
Ilex Oncology Inc. (ILXO), San Antonio, Texas Product: NM-3 isocoumarin Business: Cancer Therapeutic category: Angiogenesis Target: Vascular endothelial growth factor (VEGF) Description: Small molecu...